PubRank
Search
About
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD)
Clinical Trial ID NCT01682083
PubWeight™ 17.30
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01682083
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
MEK and the inhibitors: from bench to bedside.
J Hematol Oncol
2013
1.90
2
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy.
Biomed Res Int
2015
1.25
3
Pathways and therapeutic targets in melanoma.
Oncotarget
2014
1.17
4
Dabrafenib and its potential for the treatment of metastatic melanoma.
Drug Des Devel Ther
2012
1.16
5
B-Raf and the inhibitors: from bench to bedside.
J Hematol Oncol
2013
1.14
6
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
Oncologist
2013
1.08
7
Isolation and molecular characterization of circulating melanoma cells.
Cell Rep
2014
1.02
8
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.
Mol Cancer Ther
2014
0.92
9
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Oncogene
2015
0.90
10
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.
Front Oncol
2013
0.89
11
A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
Clin Cancer Res
2015
0.88
12
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.
Mol Cancer Ther
2014
0.86
13
Targeted therapy; from advanced melanoma to the adjuvant setting.
Front Oncol
2013
0.79
14
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.
Ther Adv Med Oncol
2015
0.78
15
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.
Drug Des Devel Ther
2015
0.77
16
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
Mod Pathol
2015
0.77
17
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.
Drug Healthc Patient Saf
2014
0.77
18
Malignant Melanoma.
Healthcare (Basel)
2013
0.75
Next 100